Original Research
Accepted on 05 Jun 2023
HECT, UBA and WWE domain containing 1 represses cholesterol efflux during CD4+ T cell activation in Sjögren’s Syndrome
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1191692
Type at least 3 characters
1,476 articles
Articles
Editorial
Published on 05 Jun 2023
Editorial: Insights in inflammation pharmacology: 2022
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1223761
- 113 views
Review
Published on 02 Jun 2023
Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1196413
- 1,024 views
Original Research
Published on 01 Jun 2023
The elucidation of the anti-inflammatory mechanism of EMO in rheumatoid arthritis through an integrative approach combining bioinformatics and experimental verification
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1195567
- 494 views
Review
Published on 01 Jun 2023
Natural flavones from edible and medicinal plants exhibit enormous potential to treat ulcerative colitis
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1168990
- 284 views
Review
Published on 01 Jun 2023
Gut microbiome-mediated mechanisms in aging-related diseases: are probiotics ready for prime time?
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1178596
- 560 views
Original Research
Accepted on 31 May 2023
Administration of protopine prevents mitophagy and acute lung injury in sepsis
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1104185
Editorial
Accepted on 30 May 2023
Editorial: Pharmacology of Autoimmune and Neuroinflammatory Disease from a Preclinical and Clinical Perspective
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1228406
Review
Accepted on 30 May 2023
Role of heparanase in ARDS through autophagy and exosome pathway (Review)
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1200782
Correction
Published on 30 May 2023
Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1219760
Review
Published on 30 May 2023
Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1186016
- 134 views
Correction
Published on 25 May 2023
Corrigendum: Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1220144
- 180 views
Original Research
Accepted on 22 May 2023
Metformin Alleviates Lung-Endothelial Hyperpermeability by Regulating Cofilin-1/PP2AC Pathway
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1211460
Systematic Review
Accepted on 22 May 2023
Risk of Venous Thromboembolism with Janus Kinase Inhibitors in Inflammatory Immune Diseases: A Systematic Review and Meta-analysis
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1189389
Editorial
Published on 19 May 2023
Editorial: Pathogenesis of diabetic foot ulcers
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1218201
- 589 views
Clinical Trial
Published on 17 May 2023
A randomized, double-blind pilot study of analgesic and anti-inflammatory effects of naproxen sodium and acetaminophen following dental implant placement surgery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1199580
- 354 views